We currently have six active independent development programs in the areas of infectious disease and cancer including:
- A fully enrolled Phase 3 clinical trial of our Allovectin-7® gene-based immunotherapeutic in patients with metastatic melanoma;
- A completed Phase 2 clinical trial of our TransVax™ therapeutic DNA vaccine designed to reduce or prevent reactivation of CMV in transplant patients;
- Completed Phase 1 clinical trials of our H5N1 pandemic influenza DNA vaccine formulated with our proprietary Vaxfectin® adjuvant;
- A Phase 1 trial of our Vaxfectin®-formulated H1N1 pandemic influenza DNA vaccine;
- Preparations for a Phase 1 trial of our Vaxfectin®-formulated CyMVectin™ prophylactic vaccine designed to prevent CMV infection before and during pregnancy to preclude fetal transmission; and
- Research-stage development of Vaxfectin®-formulated DNA vaccines for the prevention or treatment of herpes simplex type 2.
Additional programs under development by our licensees and collaborators round out the pipeline and collectively cover all stages of development from research through commercialization, across multiple disease areas, with market potential from small niche indications to general healthy populations.